COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 19 for:    MIPOMERSEN
Previous Study | Return to List | Next Study

Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis (MICA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01598948
Recruitment Status : Completed
First Posted : May 15, 2012
Last Update Posted : September 2, 2015
Information provided by (Responsible Party):
Klaus Parhofer, Ludwig-Maximilians - University of Munich

Brief Summary:
Elevated LDL-cholesterol is a major risk factor for heart disease. In patients with heart disease LDL-cholesterol should be lowered to levels below 70 mg/dl to prevent progression of disease. In most patients life style modification together with lipid lowering drug therapy is sufficient to achieve this goal. In some patients with severe forms of hypercholesterolemia, this may not be sufficient to reach goals and regular lipid apheresis (a costly and time intensive form of therapy) may be performed. Mipomersen is a new drug (apoB antisense oligonucleotide) that can lower LDL-cholesterol even in the most severe forms of LDL-hypercholesterolemia by 25-47%. It is unknown whether and to what extent mipomersen can decrease LDL-cholesterol in patients treated with regular apheresis. Phase 1 of the study will test how 6 months of weekly therapy with mipomersen affects LDL-cholesterol in patients with severe LDL-hypercholesterolemia treated with regular apheresis. Phase 2 will test in how many patients this will result in a meaningful reduction of apheresis time, apheresis frequency or if apheresis can be stopped completely.

Condition or disease Intervention/treatment Phase
Atherosclerosis LDL-hypercholesterolemia Drug: mipomersen Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Mipomersen on LDL-Cholesterol Levels in Patients With Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis
Study Start Date : August 2012
Actual Primary Completion Date : May 2015
Actual Study Completion Date : June 2015

Arm Intervention/treatment
Experimental: Mipomersen
Patients randomized to this arm will receive mipomersen 200 mg weekly
Drug: mipomersen
mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)

No Intervention: Control
patients randomized to this arm will receive no additional drug

Primary Outcome Measures :
  1. Change in pre-apheresis LDL-cholesterol (phase 1 of the study) [ Time Frame: 6 months ]
    pre-apheresis LDL-cholesterol concentration will be averaged from 3 subsequent aphereses (exactly 1 week apart) before initiation of mipomersen therapy and after 6 months of weekly apheresis therapy; apheresis conditions will not be changed.

  2. Fraction of patients in whom apheresis conditions can be modified (phase 2 of the study) [ Time Frame: 3 months ]
    In phase 2 of the study mipomersen will be given weekly. It will be evaluated in what fraction of patients this results in a decrease of apheresis time, apheresis frequency or stopping of apheresis.

Secondary Outcome Measures :
  1. change in other lipid parameters [ Time Frame: 6 months ]
    a number of additional lipid parameters will be evaluated before and during mipomersen therapy

  2. Number of participants with adverse events [ Time Frame: 9 months (phase 1 and 2 of the study) ]
  3. Plasma concentrations of mipomersen [ Time Frame: 4 days after injection ]
    pharmacokinetic sampling will be obtained following mipomersen administration at different time points during the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient fulfils German criteria for regular LDL-apheresis
  • Regular (weekly) LDL-apheresis >/= 3 months
  • The patient has fasting pre-apheresis LDL-C >/= 130 mg/dL at screening.
  • The patient is receiving a stable, maximally tolerated, lipid-lowering regimen
  • The patient has a body mass index (BMI) </= 40 kg/m2 with weight stable (± 4 kg) for > 6 weeks prior to screening.
  • Written informed consent of the patient

Exclusion Criteria:

  • The patient has experienced MI, percutaneous transluminal coronary intervention (PTCI), CABG, cerebrovascular accident, unstable angina, or acute coronary syndrome within 12 weeks of screening.
  • The patient has insulin-dependent diabetes mellitus (Type 1), or if Type 2 diabetes, HbA1c > 8% at screening.
  • The patient has New York Heart Association (NYHA) functional classification III or IV heart failure.
  • The patient has systolic blood pressure > 160 mm Hg or diastolic blood pressure > 95 mm Hg at screening (despite antihypertensive medication/therapy).
  • The patient has an active infection requiring systemic antiviral or antimicrobial therapy unless treatment expected to be completed by day 1.
  • The patient has a positive test for HIV or hepatitis B or C at screening.
  • The patient has any uncontrolled condition that may predispose to secondary hyperlipidemia such as uncontrolled hypothyroidism.
  • The patient has had a malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been adequately treated.
  • The patient has clinically significant hepatic (e.g. History of confirmed non-alcoholic steatohepatitis NASH) or renal disease or Gilbert's syndrome.
  • The patient has previously received mipomersen treatment.
  • The patient is on chronic systemic corticosteroids or anabolic agents except for replacement therapy.
  • The patient has received treatment with another investigational drug, biological agent, or device within 4 weeks of screening or 5 half-lives of the study agent, whichever is longer.
  • The patient has a current or a recent history of drug or alcohol abuse, or unwillingness to limit alcohol consumption to within moderate limits (maximum 20 g alcohol per day and 80 g alcohol per week for males; maximum 10 g alcohol per day and 40 g alcohol per week for females).
  • Patient not able to give consent.
  • Patient without legal capacity who is unable to understand the nature, scope, significance and consequences of this clinical trial.
  • Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure
  • Simultaneous participation in another clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to the beginning of the clinical trial.
  • Patient with a physical or psychiatric condition which at the investigator's discretion may put the patient at risk, may confound the trial results, or may interfere with the patient's participation in this clinical trial
  • Known or persistent abuse of medication, drugs or alcohol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01598948

Layout table for location information
University Munich
Munich, Germany, 81377
Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
Layout table for additonal information
Responsible Party: Klaus Parhofer, Professor of Medicine, Ludwig-Maximilians - University of Munich Identifier: NCT01598948    
Other Study ID Numbers: MICA
First Posted: May 15, 2012    Key Record Dates
Last Update Posted: September 2, 2015
Last Verified: September 2015
Keywords provided by Klaus Parhofer, Ludwig-Maximilians - University of Munich:
coronary heart disease
cerebrovascular disease
peripheral arterial disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents